Olorofim Receives Breakthrough Therapy Designation for Invasive Fungal Infections
The FDA has granted Breakthrough Therapy designation to olorofim for the treatment of invasive mold infections.
Emerging Treatments
Resistance-Guided Antimicrobial Therapy for Mycoplasma genitalium Infection
For infections with Mycoplasma genitalium, resistance-guided therapy using doxycycline followed by azithromycin or moxifloxacin led to high levels of microbiologic cure and low levels of de novo resistance, according to data published in Clinical Infectious Diseases. A total of 383 patients who attended Melbourne Sexual Health Centre in Australia between 2017 and 2018 with sexually…
Inverse Association Between Cannabis Use and Diabetes in Chronic HCV Infection
In a large cross-sectional study of patients with chronic hepatitis C virus (HCV) infection, cannabis use was inversely associated with diabetes.
Improved Cognition Linked to Changes in Microbiota After Fecal Transplant in Hepatic Encephalopathy
Beneficial changes in microbial composition and functionality with capsular fecal microbiota transplant lead to improved cognition in patients with cirrhosis and recurrent hepatic encephalopathy, according to study data presented at The American Association for the Study of Liver Diseases’ The Liver Meeting 2019, held November 8 to 12 in Boston, Massachusetts. In order to determine…
Oral Ibrexafungerp Effective in Vulvovaginal Candidiasis Trial
Scynexis announced positive topline results from the phase 3 VANISH 303 trial of ibrexafungerp for the treatment of vulvovaginal candidiasis (VVC) in women.
Occupational Exposure to Vaccinia Virus, Successful Treatment With Tecovirimat
Tecovirimat was safe and well-tolerated in a laboratorian who was inadvertently exposed to replication-competent vaccinia virus.
Fecal Microbiota Transplant Decreases Bloodstream Infection in C difficile
Patients with recurrent Clostridioides difficile infection who receive treatment with fecal microbiota transplantation are less likely to develop a primary bloodstream infection.
Omeprazole/Amoxicillin/Rifabutin Combination Capsule Receives FDA Approval for H pylori Treatment
The FDA has approved omeprazole magnesium, amoxicillin and rifabutin delayed-release capsules for the treatment of H pylori infection in adults.
Delafloxacin Approved for Community-Acquired Bacterial Pneumonia
The FDA has approved the supplemental NDA for Baxdela for the treatment of community acquired bacterial pneumonia in adult patients.
Onchocerciasis Treatment With Ivermectin: Results Support Semiannual Mass Drug Administration
While ivermectin plus albendazole was not superior in the treatment of onchocerciasis compared with ivermectin alone, semiannual treatment with or without albendazole was superior to annual treatment for suppressing microfilaria in the skin.
Next post in Emerging Treatments
